Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Teva
Covington
Farmers Insurance
McKinsey
Cipla
Healthtrust
Merck
Johnson and Johnson

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,442,049

« Back to Dashboard

Summary for Patent: 5,442,049
Title: Oligonucleotides for modulating the effects of cytomegalovirus infections
Abstract:Compositions and methods for modulating the effects of cytomegalovirus (CMV) infections are disclosed, comprising contacting CMV mRNA with an oligonucleotide which can bind with at least portions of the CMV RNA. In accordance with the preferred embodiments, oligonucleotides such as ISIS 2922 are designed to bind with portions of the CMV mRNAs which code for the IE1, IE2 or DNA polymerase proteins. In accordance with a preferred embodiment, methods of treatment of human cytomegalovirus are disclosed.
Inventor(s): Anderson; Kevin (Carlsbad, CA), Draper; Kenneth (Boulder, CO), Baker; Brenda (Encinitas, CA)
Assignee: Isis Pharmaceuticals, Inc. (Carlsbad, CA)
Application Number:08/009,263
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 5,442,049

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 5,442,049

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 154947 ➤ Try a Free Trial
Austria 159025 ➤ Try a Free Trial
Austria 160353 ➤ Try a Free Trial
Austria 168561 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Healthtrust
UBS
Argus Health
McKinsey
Dow
AstraZeneca
Cipla
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.